Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin

Tuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in...

Descripción completa

Detalles Bibliográficos
Autores: Valverde-Fraga, Lorena, Haddad, Razan, Alrabadi, Nasr, Sánchez Poza, María Sandra, Remuñán López, Carmen, Csaba, Noemi Stefania
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Santiago de Compostela (USC)
Repositorio:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Idioma:inglés
OAI Identifier:oai:minerva.usc.gal:10347/31219
Acceso en línea:http://hdl.handle.net/10347/31219
Access Level:acceso abierto
id ES_45d9e638698656e2ff47b5d23b2cb70e
oai_identifier_str oai:minerva.usc.gal:10347/31219
network_acronym_str ES
network_name_str España
repository_id_str
spelling Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutinValverde-Fraga, LorenaHaddad, RazanAlrabadi, NasrSánchez Poza, María SandraRemuñán López, CarmenCsaba, Noemi StefaniaTuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in high doses and for long periods of time. These therapeutic regimens are associated with many side effects and high rates of drug resistance. To overcome these problems, this study aims at developing a nanosystem for the improved delivery of antibiotics, with potential application in pulmonary delivery. Chitosan-based nanomaterials are widely used in biomedical applications, due to their biodegradability and biocompatibility, as well as their potential antimicrobial effects and lack of toxicity. In addition, this polymer is particularly attractive for mucosal delivery due to its bioadhesive properties. Therefore, the structure of the proposed nanocarrier consists of a chitosan shell and a lipid core with a combination of different oils and surfactants to allow optimal association of the hydrophobic drug rifabutin. These nanocapsules were characterized in terms of size, polydispersity index, surface charge, morphology, encapsulation efficiency and biological stability. The release kinetics of the drug-loaded nanostructures was evaluated in simulated lung media. Moreover, in vitro studies in different cell models (A549 and Raw 264.7 cells) demonstrated the safety of the nanocapsules as well as their efficient internalization. An antimicrobial susceptibility test was performed to evaluate the efficacy of the rifabutin-loaded nanocapsules against Mycobacterium phlei. This study indicated complete inhibition for antibiotic concentrations within the expected susceptibility range of Mycobacterium (≤ 0.25–16 mg/L)ElsevierUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades CrónicasUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía FarmacéuticaUniversidade de Santiago de Compostela. Departamento de Microbioloxía e Parasitoloxía20232023-05-3120232023-05-31journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10347/31219reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostelainstname:Universidad de Santiago de Compostela (USC)InglésengAgencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-107500RB-I00 BIOMORPHIC PLATFORMS FOR THE PULMONARY DELIVERY OF NANOTHERAPEUTICSopen accesshttp://purl.org/coar/access_right/c_abf20928© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:minerva.usc.gal:10347/312192026-06-15T12:47:27Z
dc.title.none.fl_str_mv Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
title Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
spellingShingle Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
Valverde-Fraga, Lorena
title_short Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
title_full Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
title_fullStr Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
title_full_unstemmed Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
title_sort Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
dc.creator.none.fl_str_mv Valverde-Fraga, Lorena
Haddad, Razan
Alrabadi, Nasr
Sánchez Poza, María Sandra
Remuñán López, Carmen
Csaba, Noemi Stefania
author Valverde-Fraga, Lorena
author_facet Valverde-Fraga, Lorena
Haddad, Razan
Alrabadi, Nasr
Sánchez Poza, María Sandra
Remuñán López, Carmen
Csaba, Noemi Stefania
author_role author
author2 Haddad, Razan
Alrabadi, Nasr
Sánchez Poza, María Sandra
Remuñán López, Carmen
Csaba, Noemi Stefania
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas
Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
Universidade de Santiago de Compostela. Departamento de Microbioloxía e Parasitoloxía
description Tuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in high doses and for long periods of time. These therapeutic regimens are associated with many side effects and high rates of drug resistance. To overcome these problems, this study aims at developing a nanosystem for the improved delivery of antibiotics, with potential application in pulmonary delivery. Chitosan-based nanomaterials are widely used in biomedical applications, due to their biodegradability and biocompatibility, as well as their potential antimicrobial effects and lack of toxicity. In addition, this polymer is particularly attractive for mucosal delivery due to its bioadhesive properties. Therefore, the structure of the proposed nanocarrier consists of a chitosan shell and a lipid core with a combination of different oils and surfactants to allow optimal association of the hydrophobic drug rifabutin. These nanocapsules were characterized in terms of size, polydispersity index, surface charge, morphology, encapsulation efficiency and biological stability. The release kinetics of the drug-loaded nanostructures was evaluated in simulated lung media. Moreover, in vitro studies in different cell models (A549 and Raw 264.7 cells) demonstrated the safety of the nanocapsules as well as their efficient internalization. An antimicrobial susceptibility test was performed to evaluate the efficacy of the rifabutin-loaded nanocapsules against Mycobacterium phlei. This study indicated complete inhibition for antibiotic concentrations within the expected susceptibility range of Mycobacterium (≤ 0.25–16 mg/L)
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-05-31
2023
2023-05-31
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10347/31219
url http://hdl.handle.net/10347/31219
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-107500RB-I00 BIOMORPHIC PLATFORMS FOR THE PULMONARY DELIVERY OF NANOTHERAPEUTICS
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname:Universidad de Santiago de Compostela (USC)
instname_str Universidad de Santiago de Compostela (USC)
reponame_str Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
collection Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407188890419200
score 15.811543

Similares en LA Referencia